US Pharma MarketingBiogen investigated by Italian regulator over multiple sclerosis ‘market abuse’ claims
Italy’s antitrust agency, the Italian Competition Authority (AGCM), is investigating Biogen and its Italian subsidiary over claims it is abusing its market position regarding a test for its multipl Italy’s antitrust agency, the Italian Competition Authority (AGCM), is investigating Biogen and its Italian subsidiary over claims it is abusing its market position regarding a test for its multiple sclerosis drug Tysabri (natalizumab). Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation Awards…
Italy’s antitrust agency, the Italian Competition Authority (AGCM), is investigating Biogen and its Italian subsidiary over claims it is abusing its market position regarding a test for its multiple sclerosis drug Tysabri (natalizumab).
Source: FiercePharma